{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T10:31:57Z","timestamp":1793442717032,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["823B2076"],"award-info":[{"award-number":["823B2076"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471865"],"award-info":[{"award-number":["82471865"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jconrel.2026.115423","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:45:01Z","timestamp":1790783101000},"page":"115423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PB","title":["OX40 ligand-engineered dendritic cell nanovesicles potentiate antitumor immunity through dual-mode T cell activation"],"prefix":"10.1016","volume":"399","author":[{"given":"Zhongqian","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuyuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jconrel.2026.115423_bb0005","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review","volume":"234","author":"Farhood","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"103","key":"10.1016\/j.jconrel.2026.115423_bb0010","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adf4726","article-title":"Architects of immunity: how dendritic cells shape CD8(+) T cell fate in cancer","volume":"10","author":"Bhandarkar","year":"2025","journal-title":"Sci. Immunol."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115423_bb0015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41573-024-00974-9","article-title":"Enhancing in situ cancer vaccines using delivery technologies","volume":"23","author":"Gong","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115423_bb0020","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41596-022-00713-7","article-title":"Nanocarriers based on bacterial membrane materials for cancer vaccine delivery","volume":"17","author":"Zhao","year":"2022","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115423_bb0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115423_bb0030","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1172\/JCI31205","article-title":"DC-based cancer vaccines","volume":"117","author":"Gilboa","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115423_bb0035","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1038\/nbt1262","article-title":"An essential role for Akt1 in dendritic cell function and tumor immunotherapy","volume":"24","author":"Park","year":"2006","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115423_bb0040","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41565-022-01098-0","article-title":"A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy","volume":"17","author":"Liu","year":"2022","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115423_bb0045","article-title":"Cell membrane-derived vesicle: a novel vehicle for cancer immunotherapy","volume":"13","author":"Xu","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115423_bb0050","first-page":"100","article-title":"Cell membrane coating technology: a promising strategy for biomedical applications","volume":"11","author":"Liu","year":"2019","journal-title":"Nanomicro Lett."},{"key":"10.1016\/j.jconrel.2026.115423_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113620","article-title":"Engineered dendritic cells-derived extracellular vesicles for cancer immunotherapy","volume":"381","author":"Coelho","year":"2025","journal-title":"J. Control. Release"},{"issue":"23","key":"10.1016\/j.jconrel.2026.115423_bb0060","doi-asserted-by":"crossref","DOI":"10.4028\/b-XDTcg5","article-title":"Locoregional immune checkpoint blockade and remodeling of lymph nodes by engineered dendritic cell-derived exosomes for suppressing tumor progression and metastasis","volume":"12","author":"Wang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"issue":"17","key":"10.1016\/j.jconrel.2026.115423_bb0065","article-title":"CCR7 mediated mimetic dendritic cell vaccine homing in lymph node for head and neck squamous cell carcinoma therapy","volume":"10","author":"Xu","year":"2023","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115423_bb0070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13045-020-00939-6","article-title":"Dendritic cell biology and its role in tumor immunotherapy","volume":"13","author":"Wang","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115423_bb0075","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-024-02179-5","article-title":"Current trends in sensitizing immune checkpoint inhibitors for cancer treatment","volume":"23","author":"Wei","year":"2024","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115423_bb0080","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1053\/j.seminoncol.2010.09.013","article-title":"Signaling through OX40 enhances antitumor immunity","volume":"37","author":"Jensen","year":"2010","journal-title":"Semin. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115423_bb0085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2017-07-741025","article-title":"The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy","volume":"131","author":"Buchan","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jconrel.2026.115423_bb0090","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1158\/2326-6066.CIR-15-0228","article-title":"Gp96-Ig\/Costimulator (OX40L, ICOSL, or 4-1BBL) combination vaccine improves T-cell priming and enhances immunity, memory, and tumor elimination","volume":"4","author":"Fromm","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115423_bb0095","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.7150\/thno.83495","article-title":"OX40L-armed oncolytic virus boosts T-cell response and remodels tumor microenvironment for pancreatic cancer treatment","volume":"13","author":"Liu","year":"2023","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115423_bb0100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s40425-018-0454-3","article-title":"Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy","volume":"6","author":"Fromm","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2026.115423_bb0105","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.biomaterials.2018.08.018","article-title":"Bioengineered stem cell membrane functionalized nanocarriers for therapeutic targeting of severe hindlimb ischemia","volume":"185","author":"Bose","year":"2018","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115423_bb0110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41565-023-01533-w","article-title":"A modular approach to enhancing cell membrane-coated nanoparticle functionality using genetic engineering","volume":"19","author":"Krishnan","year":"2024","journal-title":"Nat. Nanotechnol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115423_bb0115","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3390\/jfb6020454","article-title":"Cell surface and membrane engineering: emerging technologies and applications","volume":"6","author":"Saeui","year":"2015","journal-title":"J. Funct. Biomater."},{"issue":"14","key":"10.1016\/j.jconrel.2026.115423_bb0120","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1021\/acs.nanolett.1c00680","article-title":"RBD-modified bacterial vesicles elicited potential protective immunity against SARS-CoV-2","volume":"21","author":"Yang","year":"2021","journal-title":"Nano Lett."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115423_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12429","article-title":"Synthetic biology-based bacterial extracellular vesicles displaying BMP-2 and CXCR4 to ameliorate osteoporosis","volume":"13","author":"Liu","year":"2024","journal-title":"J. Extracell. Vesicles"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115423_bb0130","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1038\/s41467-024-50950-5","article-title":"Reprogramming the tumor immune microenvironment using engineered dual-drug loaded Salmonella","volume":"15","author":"Nguyen","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115423_bb0135","doi-asserted-by":"crossref","first-page":"8414","DOI":"10.1038\/s41467-024-52745-0","article-title":"Cytolysin A is an intracellularly induced and secreted cytotoxin of typhoidal Salmonella","volume":"15","author":"Krone","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115423_bb0140","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1038\/ncomms7198","article-title":"The assembly dynamics of the cytolytic pore toxin ClyA","volume":"6","author":"Benke","year":"2015","journal-title":"Nat. Commun."},{"issue":"7247","key":"10.1016\/j.jconrel.2026.115423_bb0145","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nature08026","article-title":"The structure of a cytolytic alpha-helical toxin pore reveals its assembly mechanism","volume":"459","author":"Mueller","year":"2009","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115423_bb0150","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00281-024-01034-5","article-title":"Current advancements in cellular immunotherapy for autoimmune disease","volume":"47","author":"Berry","year":"2025","journal-title":"Semin. Immunopathol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115423_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17050550","article-title":"A review on the stability challenges of advanced biologic therapeutics","volume":"17","author":"Sarvepalli","year":"2025","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115423_bb0160","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s10555-024-10184-9","article-title":"OX40\/OX40 ligand and its role in precision immune oncology","volume":"43","author":"Thapa","year":"2024","journal-title":"Cancer Metastasis Rev."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115423_bb0165","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221166","article-title":"OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs","volume":"220","author":"Yang","year":"2023","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.115423_bb0170","first-page":"689","article-title":"Gene-guided OX40L anchoring to tumor cells for synergetic tumor \u201cself-killing\u201d immunotherapy","volume":"25","author":"Lin","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.jconrel.2026.115423_bb0175","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.2147\/IJN.S479434","article-title":"Enhanced antitumor immunity through T cell activation with optimized tandem double-OX40L mRNAs","volume":"20","author":"Deng","year":"2025","journal-title":"Int. J. Nanomedicine"},{"issue":"12","key":"10.1016\/j.jconrel.2026.115423_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202006484","article-title":"Immune cell membrane-coated biomimetic nanoparticles for targeted cancer therapy","volume":"17","author":"Oroojalian","year":"2021","journal-title":"Small"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115423_bb0185","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40580-022-00328-4","article-title":"Membrane-wrapped nanoparticles for photothermal cancer therapy","volume":"9","author":"Aboeleneen","year":"2022","journal-title":"Nano Converg."},{"issue":"18","key":"10.1016\/j.jconrel.2026.115423_bb0190","article-title":"Cell membrane as a promising therapeutic target: from materials design to biomedical applications","volume":"63","author":"Wu","year":"2024","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115423_bb0195","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.apsb.2019.01.011","article-title":"Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application","volume":"9","author":"Xia","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115423_bb0200","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1021\/acsnano.6b06477","article-title":"Nanoparticles coated with neutrophil membranes can effectively treat cancer metastasis","volume":"11","author":"Kang","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115423_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113648","article-title":"Inhalable neutrophil-mimicking nanoparticles for chronic obstructive pulmonary disease treatment","volume":"381","author":"Yu","year":"2025","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115423_bb0210","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.7150\/thno.50928","article-title":"Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes","volume":"11","author":"Han","year":"2021","journal-title":"Theranostics"},{"issue":"16","key":"10.1016\/j.jconrel.2026.115423_bb0215","doi-asserted-by":"crossref","first-page":"15345","DOI":"10.1021\/acsnano.4c14305","article-title":"Engineered macrophage membrane-camouflaged nanodecoys reshape the infectious microenvironment for efficient periodontitis treatment","volume":"19","author":"Lin","year":"2025","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.jconrel.2026.115423_bb0220","first-page":"911","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat. Can."},{"issue":"25","key":"10.1016\/j.jconrel.2026.115423_bb0225","article-title":"Novel personalized cancer vaccine using tumor extracellular vesicles with attenuated tumorigenicity and enhanced immunogenicity","volume":"11","author":"Han","year":"2024","journal-title":"Adv Sci (Weinh)"},{"issue":"22","key":"10.1016\/j.jconrel.2026.115423_bb0230","article-title":"Rethinking antigen source: cancer vaccines based on whole tumor cell\/tissue lysate or whole tumor cell","volume":"10","author":"Diao","year":"2023","journal-title":"Adv Sci (Weinh)"},{"issue":"8","key":"10.1016\/j.jconrel.2026.115423_bb0235","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/eji.200939448","article-title":"Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo","volume":"39","author":"Redmond","year":"2009","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115423_bb0240","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115423_bb0245","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115423_bb0250","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926008278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926008278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:50:31Z","timestamp":1793440231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926008278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":50,"alternative-id":["S0168365926008278"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115423","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OX40 ligand-engineered dendritic cell nanovesicles potentiate antitumor immunity through dual-mode T cell activation","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115423","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115423"}}